» Articles » PMID: 32292281

Analytical Performance Assessment and Improvement by Means of the Failure Mode and Effect Analysis (FMEA)

Overview
Specialty Biochemistry
Date 2020 Apr 16
PMID 32292281
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Laboratories minimize risks through quality control but analytical errors still occur. Risk management can improve the quality of processes and increase patient safety. This study aims to use the failure mode and effect analysis (FMEA) to assess the analytical performance and measure the effectiveness of the risk mitigation actions implemented.

Materials And Methods: The measurands to be included in the study were selected based on the measurement errors obtained by participating in an External Quality Assessment (EQA) Scheme. These EQA results were used to perform an FMEA of the year 2017, providing a risk priority number that was converted into a Sigma value (σ). A root-cause analysis was done when σ was lower than 3. Once the causes were determined, corrective measures were implemented. An FMEA of 2018 was carried out to verify the effectiveness of the actions taken.

Results: The FMEA of 2017 showed that alkaline phosphatase (ALP) and sodium (Na) presented a σ of less than 3. The FMEA of 2018 revealed that none of the measurands presented a σ below 3 and that σ for ALP and Na had increased.

Conclusions: Failure mode and effect analysis is a useful tool to assess the analytical performance, solve problems and evaluate the effectiveness of the actions taken. Moreover, the proposed methodology allows to standardize the scoring of the scales, as well as the evaluation and prioritization of risks.

Citing Articles

Risk management in POCT blood glucose monitoring: FMEA approach aligned with ISO 15189:2022.

Luan X, Ke L, Feng M, Peng W, Luo H, Xue H PLoS One. 2025; 20(3):e0319817.

PMID: 40063652 PMC: 11892846. DOI: 10.1371/journal.pone.0319817.


Healthcare Application of Failure Mode and Effect Analysis (FMEA): Is There Room in the Infectious Disease Setting? A Scoping Review.

Vecchia M, Sacchi P, Marvulli L, Ragazzoni L, Muzzi A, Polo L Healthcare (Basel). 2025; 13(1).

PMID: 39791689 PMC: 11719677. DOI: 10.3390/healthcare13010082.


Analysis of Medico-Legal Complaint Data: A Retrospective Study of Three Large Italian University Hospitals.

Di Fazio N, Scopetti M, Delogu G, La Russa R, Foti F, Grassi V Healthcare (Basel). 2023; 11(10).

PMID: 37239691 PMC: 10218680. DOI: 10.3390/healthcare11101406.


Proactive Risk Assessment Through Failure Mode and Effect Analysis (FMEA) for Haemodialysis Facilities: A Pilot Project.

La Russa R, Fazio V, Ferrara M, Di Fazio N, Viola R, Piras G Front Public Health. 2022; 10:823680.

PMID: 35400067 PMC: 8987154. DOI: 10.3389/fpubh.2022.823680.


Development and Application of Computerized Risk Registry and Management Tool Based on FMEA and FRACAS for Total Testing Process.

Chang J, Yoo S, Kim S Medicina (Kaunas). 2021; 57(5).

PMID: 34065022 PMC: 8151538. DOI: 10.3390/medicina57050477.

References
1.
Westgard J . Perspectives on quality control, risk management, and analytical quality management. Clin Lab Med. 2013; 33(1):1-14. DOI: 10.1016/j.cll.2012.10.003. View

2.
Capunzo M, Cavallo P, Boccia G, Brunetti L, Pizzuti S . A FMEA clinical laboratory case study: how to make problems and improvements measurable. Clin Leadersh Manag Rev. 2004; 18(1):37-41. View

3.
Lippi G, Plebani M . A Six-Sigma approach for comparing diagnostic errors in healthcare-where does laboratory medicine stand?. Ann Transl Med. 2018; 6(10):180. PMC: 5994534. DOI: 10.21037/atm.2018.04.02. View

4.
Xia Y, Xue H, Yan C, Li B, Zhang S, Li M . Risk analysis and assessment based on Sigma metrics and intended use. Biochem Med (Zagreb). 2018; 28(2):020707. PMC: 6039164. DOI: 10.11613/BM.2018.020707. View

5.
Franklin B, Shebl N, Barber N . Failure mode and effects analysis: too little for too much?. BMJ Qual Saf. 2012; 21(7):607-11. DOI: 10.1136/bmjqs-2011-000723. View